HIV protection with just two shots a year: FDA approves Gilead drug

Taking stock of the drug industry, from the lab to the medicine chest

June 25, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Good evening. This week only, get 50% off your first year of STAT+ and enjoy unlimited access to award-winning journalism, premium data tools, discounted event tickets, and much more. Thanks for reading.

APStock STAT+ | Regeneron seeks to revamp the controversial relationships between pharma and patient charities After slashing its funding to the charity Good Days, the company is hoping to widen patient access to its eye drug without also benefiting rivals. By Ed Silverman STAT+ | Health insurers promise to reduce barriers to care under pressure from Trump administration Under Trump administration pressure, health insurers promise to limit and speed up prior authorizations. A similar pledge in 2018 was ineffective. By Tara Bannow and Chelsea Cirruzzo STAT+ | Nuvalent says its ROS1-targeted drug shrank lung tumors in patients who failed other options The company's drug, zidesamtinib, which targets ROS1, was tested in patients whose tumors had stopped responding to other medications. By Matthew Herper Molly Ferguson for STAT Balkanization of vaccine policy raises concerns about vaccine uptake, insurance coverage, experts warn Firing of CDC vaccine experts leads U.S. toward a balkanized vaccination policy where guidance may depend on personal preference, not scientific expertise. By Helen Branswell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser